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Vescalagin and castalagin reduce the toxicity of amyloid-beta42 
oligomers through the remodelling of its secondary structure
Ana R. Araújoa,b,c, Sérgio Cameroa,b,d, Pablo Taboadae, Rui L. Reisa,b,c and Ricardo A. Piresa,b,c,* 
The isomers vescalagin and castalagin protect SH-SY5Y cells from 
Aβ42-mediated death. This is achieved better by vescalagin due to 
the spatial organization of its OH group at the C1 position of the 
glycosidic chain, improving its capacity to remodel the secondary 
structure of toxic Aβ42 oligomers.
Alzheimer´s Disease (AD) is the most common cause of 
dementia, characterized by cognitive impairment and memory 
loss.1 The most characteristic hallmarks of AD are the presence 
of intracellular neurofibrillary tangles (of hyperphosphorylated 
Tau protein) in the affected neurons, and the deposition of 
extracellular plaques of amyloid-β (Aβ) peptides in the 
hippocampus and entorhinal cortex. In the case of the amyloid 
deposits, they are usually composed of Aβ of different lengths, 
i.e. between 38 and 43 amino acids. Aβ is produced by neurons 
during the sequential proteolytic cleavage of amyloid precursor 
protein (APP).2 Aβ (1-42) (Aβ42) is the less abundant species, 
however, it is the most amyloidogenic due to its higher 
propensity to self-assemble into supramolecular aggregates, 
which has been linked with the predominance of hydrophobic 
amino acid residues at its C-terminus.3 Aβ42 can exist in several 
forms, e.g. monomers, oligomers or fibrils, however, its 
oligomeric species are reported to be the most cytotoxic4. They 
comprise different levels of association, such as dimers, trimers 
and higher hierarchical assemblies that lead to the formation of 
protofibrils, the intermediates of the Aβ fibril formation and 
elongation.5, 6 It has been also reported that these oligomeric 
structures spread out through the brain and trigger the 
hyperphosphorylation of Tau leading to the formation of the 
neurofibrillary tangles.7, 8 Despite the strong body of evidence 
that supports the pivotal role of oligomers on Aβ toxicity, there 
is no agreement in the literature on their supramolecular 
organization. While some authors report them as being 
unstructured9, others show that they present an anti-parallel β-
sheet structure (in contrast to the parallel organization of the 
fibrils).10
Polyphenolic compounds are able to interact with Aβ4211-14. 
This interaction is mainly driven by: the binding of the 
polyphenols’ aromatic rings with the amino and sulfhydryl 
groups of the peptide; or directly through - stacking 
between the same aromatic rings and the Aβ42 aromatic 
aminoacidic residues (e.g. phenylalanine).15 Based on these 
studies we evaluated the capacity of two cork polyphenols, i.e. 
vescalagin (1) and castalagin (2) (chemical structures presented 
in Fig. 1) to remodel the supramolecular organization of 
oligomeric Aβ42 into non-cytotoxic forms. The extraction and 
identification of each compound was optimized and performed 
following a previous work16 (chemical characterization is 
presented in Figs. S1-S7).
We started by evaluating the capacity of 1 and 2 to reduce 
the fibrillization of Aβ42 using the Thioflavin-T (ThT) assay. ThT 
binds to β-sheet-rich structures mainly through π-π interactions 
and displays enhanced fluorescence in the presence of amyloid 
fibrils.17, 18 Initial ThT fluorescence was monitored for Aβ42 
alone, showing the characteristic sigmoidal curve of peptide 
fibrillization (Figs. 2A and S12). To guarantee that there is no 
interference from the fluorescence of 1 and 2 in the results, 
their spectra were acquired in the absence of Aβ42 (Figs. S8 and 
S9). At the excitation/emission wavelengths used for the ThT 
analysis, no fluorescence was observed for 1 and 2 showing that 
the ThT data is devoid of interference from the polyphenols 
themselves. After guaranteeing that the experimental 
conditions were set to provide meaningful data, Aβ42 (25μM in
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Fig. 1 Chemical structure of the polyphenols vescalagin (1) and castalagin (2) 
extracted and purified from cork powder.
the monomeric form) was incubated at room temperature with 
ThT (25μM) and its fluorescence associated with the Aβ42 
secondary structure in the presence of 1 or 2 (Aβ42:polyphenol
molar ratios of 1:0.5; 1:1 and 1:2) was followed over 140h (apx. 
6 days). From Figs. 2A and S13, it is clear the reduction of Aβ42 
fibrillization in the presence of 1 or 2 in a concentration 
dependent manner, where 1 was able to completely inhibit 
aggregation at an Aβ42:polyphenol ratio of 1:1, while 2 could 
only achieve this outcome at a ratio of 1:2.
We also tested the capacity of 1 and 2 to disassemble the 
Aβ42 pre-formed fibrils (Figs. 2B and S14). In this case, 1 and 2 
were added at the plateau phase (after apx. 6 days of peptide 
incubation). The ThT fluorescence decreased immediately after 
the addition of the polyphenols (t=0-24h). Incubation of fibrils 
with an equimolar concentration of 1 reduced markedly the ThT 
fluorescence to apx. 20% at t∼20min and to apx. 3% after 1h 
(Fig. S14A). An almost coincident curve was recorded when a 
higher ratio of 1 was used (i.e. 1:2). In the case of 2 the ThT 
fluorescence reduced to apx. 50% at t∼20min and to apx. 20% 
after 1h (Fig. S14B). In both cases, assembly and disassembly, 1 
seems to be more efficient in disrupting the β-sheet rich 
supramolecular assemblies of Aβ42. Despite the reduction on 
ThT fluorescence, this method is not completely reliable to 
guarantee that no cytotoxic assemblies are formed. In fact, 
there are some reports in the literature that show that 
oligomer-specific antiparallel β-sheets do not exhibit ThT 
fluorescence, showing that this technique should not be 
considered on its own to evaluate the remodelling of Aβ42 into 
non-cytotoxic forms. Considering these methodological 
constraints, we needed a complementary technique to ensure 
that we are indeed reducing the presence of Aβ42 oligomers. 
We then evaluated by Western Blot (WB) if there was an 
observable reduction of the size of the peptide aggregates in 
the presence of 1 and 2 both during Aβ42 assembly and 
disassembly (Figs. 2C-D and S15-S19). Overall, during assembly 
(i.e. 7 days of incubation, Fig. 2C and S15-S16) there is a clear 
reduction of Aβ42 oligomers (between 2-3 peptide units, i.e. 15-
10kDa) from ∼35% to ∼18% in the presence of 1. In contrast, in 
the presence of 2, only at the highest ratio 1:2, it starts to be 
observed a reduction of the oligomeric species, to ∼ 27%. 
Importantly, we also observe a significant loss of larger Aβ42 
species (of different sizes: 250-55kDa) for all the tested ratios 
(Fig. 2C). In the case of the Aβ42 disassembly (Figs. 2D and S17-
S18) the presence of 2 seems to be more effective in the 
reduction of the fibrillar/larger species. In addition, overall both 
during assembly and disassembly, it is always detected a 
reduction of the Aβ42 species detected by the 6E10 monoclonal 
antibody. These results are consistent with a remodelling of the 
supramolecular organization of Aβ42 into structures that are 
not able to be detected by immunostaining with 6E10 (reported 
to detect different types of supramolecular Aβ42 assemblies).5 
Possible explanations are related with the 6E10 binding sites 
that, either are being occupied by the polyphenols, either the 
remodelled aggregates do not expose them on their surface. In 
any case, it is clear that 1 and 2 are able to partially alter the 
Aβ42 supramolecular assemblies into forms that are not 
detectable by ThT nor by the 6E10 antibody.
While ThT and WB assays confirmed the capacity of 1 and 2 
to alter the aggregation pathway of Aβ42, it is important to look 
for the structural features that guide the observed remodelling. 
We then used circular dichroism (CD) to confirm if the peptide 
secondary structure is actually affected by the presence of 1 and 
2. After 7 days of incubation, we observed that Aβ42 alone 
presents a characteristic negative peak, at apx. 218 nm and a 
positive peak at ∼197nm (Fig. S20). This spectral profile has 
been previously reported for the β-sheet conformation of 
oligomers.19, 20 Surprisingly, the addition of 1 or 2 (at the 
different ratios) does not change the overall spectral profile. 
However, both peaks present a blue shift after the addition of 1 
or 2, showing that they promote an alteration of the β-sheet 
conformation of the Aβ42 supramolecular assemblies (Fig. S20).
Fig. 2 A. Aggregation of Aβ42 (25μM) followed by ThT fluorescence upon 
incubation over 140h under different Aβ42:polyphenol molar ratios, i.e. 1:0.5, 1:1 
and 1:2. B. Disassembly of the fibrillar Aβ42 (25μM) followed by ThT fluorescence 
using the same Aβ42:polyphenol ratios. All measurements were recorded under 
constant agitation at 37°C and were monitored during 24h. Error bars = SD; n = 3. 
C-D. Relative densitometric bar graphs of C. Aβ42 (25μM) assembly and D. Aβ42 
(25μM) disassembly quantified by WB (using the antibody 6E10); experiments 
conducted at 37°C in phosphate buffer, during C. 7days or D. 24h; Error bars = SD, 
* p < 0.05, ** p < 0.01 and *** p < 0.001 vs control 25μM Aβ42; n = 3.
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Fig. 3 A. Loss of parallel β-sheets by Aβ42 (25μM) monitored by CD upon 
incubation with 1 and 2 under constant agitation at 37°C, during 24h. CD data 
were fitted using BeStSel - RMSD: 1.0283; NRMSD: 0.04966. B-C. 1 and 2 (25μM) 
induced the refolding of Aβ42 (25μM) into spherical assemblies detected by AFM 
and STEM, respectively. Scale bars 2μm (AFM) and 500nm (STEM).
To evaluate if this shift was concomitant with a redistribution of 
the different types of the peptide secondary structure we fitted 
the CD spectra with BeStSel method for secondary structure 
estimation (Table S1).21 The results showed that Aβ42 fibrils 
during the disassembly experiments (24h) are mainly composed 
by parallel β-sheet assemblies (Fig. 3A).21 We also found that 
both 1 and 2 decrease the parallel β-sheets content and 
promote a rearrangement of the peptide into helix, anti-parallel 
β-sheets and other types of secondary structures. Importantly, 
only 1 is able to eliminate the parallel arrangement without any 
anti-parallel organization. The remodelling of Aβ42 promoted 
by 2 leads to the appearance of anti-parallel β-sheets. In the 
case of the assembly experiments, the CD quantification (Table 
S1) is consistent with the ThT and WB analysis (Figs. 2A and 2C), 
showing a higher capacity of 1 to reduce the β-sheet content of 
Aβ42, when compared to 2.
The morphology of the generated assemblies was also 
monitored by AFM and STEM. Both 1 and 2 are highly efficient 
in remodelling the Aβ42 fibrils (Figs. 3B-C and S22-S23). Both 
during assembly (24h) and disassembly (7days) experiments 
peptide aggregates were detected instead of long fibrils. Of 
note is that the oligomers observed in the Aβ42 control, i.e. in 
the form of 10-15nm aggregates disappear in the presence of 1 
or 2, giving rise to non-fibrillar larger aggregates. AFM images 
(Fig. S22) also confirmed that the remodelling of the Aβ42 
morphology is concentration-dependent.
Finally, considering that the association of the exposed 
hydrophobic peptide domains are the main driving forces for 
the intramolecular interactions, we evaluated the peptide- 
ligand binding energies (for both 1 and 2) at the thermodynamic 
level using isothermal titration calorimetry (ITC)22 (Table 1 and 
Fig. S24). In both cases ΔG is negative, indicating a tendency for 
the interaction to occur and that the formed peptide:ligand 
complex is thermodynamically stable. Our results show 
negative values for the other two thermodynamic parameters,
Table 1 ITC analysis of the interaction between Aβ42 and 1 or 2 under a 
Aβ42:polyphenol ratio of 1:1: K1 (mol-1)= 1.26e6±0.18; K2 (mol-1)= 4.54e6±0.56 
using a one binding site model.
i.e. ∆H and ∆S. The enthalpic property, i.e. ΔH, is a measure of 
the average energy released along the interaction process 
between the peptide and the ligand.23 In this context, the 
negative value of ∆H (similarly to the results obtained for ∆G) 
show that the formation of peptide:ligand complexes are 
energetically favourable; however, the negative values for ∆S 
indicate that the complexes are entropically unfavourable. This 
outcome can be explained by a progressive rupture of the 
hydration layer and release of counterions caused by the ring 
torsional degrees of freedom of each compound. In the case of 
1 and 2, there is a covalent link between their aromatic rings 
generating a significant structural rigidity that is probably 
reflected in their interaction with Aβ42. This rigidity might 
affect the hydrophobic interactions (e.g. π-π stacking) 
promoting an increase on hydrogen bonding between the 
polyphenols and Aβ42. In fact, 1 is reported to be more 
hydrophilic than 2 and with increased capacity to participate in 
hydrogen bonding due to the spatial organization of its OH at 
position C1 of the glycosidic chain.24 In addition, the interaction 
can also comprise charge shielding effects and/or molecular 
rearrangements of the ligand/peptide complexes. Interestingly, 
ITC data is consistent with the ThT, WB and CD results by 
suggesting that the complexes formed between compound 1 
and Aβ42 are more stable and energetically more favourable.
Our data suggests that both 1 and 2 are interacting with 
Aβ42, remodelling its supramolecular organization and 
morphological presentation, reducing the concentration of 
oligomers. To evaluate if compounds 1 and 2 are in fact able to 
reduce the Aβ42-mediated cell death we performed a 
cytotoxicity assay using SH-SY5Y cells. To this end, Aβ42 (in the 
monomeric form) was incubated with SH-SY5Y cells and their 
viability was quantified after 24h using standardized MTS and 
Live/Dead assays. When Aβ42 was added at a concentration of 
25μM, there was a decrease on cell viability to ∼50% (Fig. S25). 
Maintaining this concentration of Aβ42, we added different 
concentrations of 1 and 2 (i.e. 12.5μM, 25μM and 50μM). 
Cellular metabolic activity is recovered to ∼100%, after 24h (Fig. 
S29A) for all the tested conditions. In addition, Live/Dead assay 
(Figs. 4A) confirmed the same tendency showing that both 1 
and 2 are able to rescue cell viability after 24h of incubation. 
Quantification of the percentage of live cells (Fig. S28) revealed 
that the cytotoxicity of Aβ42 resulted in less than 50% of live 
cells, however, 1 and 2 were able to rescue cells from death to 
a level similar to the control experiments, i.e. ∼100% of live 
cells. To understand if Aβ42 was still present in the cellular 
space, we visualized the peptide by immunofluorescence (using 
the 6E10 monoclonal antibody, Figs. 4B and S30). The results 
clearly show a marked reduction in the fluorescence for Aβ42 
when 1 (but
ΔH
(cal mol-1)
ΔG
(cal mol-1)
ΔS
(cal mol-1 K-1)
Aβ42:1 ratio 1:1 -9.28e4±0.91 -11051±502 -274±61
Aβ42:2 ratio 1:1 -4.58e4±0.22 -9082±290 -123±45
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Fig. 4 A. Live/Dead assay using SH-SY5Y cells incubated with different 
Aβ42:polyphenol ratios during 24h (green: live cells; red: dead cells). B. 
Immunofluorescence analysis of Aβ42 aggregates in the SH-SY5Y cell culture 
visualized by confocal microscopy (mAb 6E10, green) after incubation with 1 or 2 
for 24h (Aβ42: green, cell nuclei: blue). Scale bar = 50 μm.
not 2) is added to the culture medium, showing that 1 is clearly 
more effective than 2 in reducing the presence of Aβ42 
aggregates in the cell culture. Of note, in the case of 1 (but not 
of 2) the reduction in fluorescence is also concentration-
dependent, being able to reduce the fluorescence to ∼35% (Fig. 
S29B).
Overall, our data suggests that there is a higher propensity 
of 1 to interact with Aβ42 when compared with 2. While being 
surprising, as the structural difference between 1 and 2 is only 
in the spatial organization of their OH group at the C1 position of 
the glycosidic chain, it has been already reported that this 
difference leads to higher reactivity, increased polarity and 
lower lipophilicity of 1 compared to 2.24 Overall, 1 is able not 
only to rearrange the Aβ42 secondary structure, leading to the 
formation of non-cytotoxic structures (without their typical 
antiparallel β-sheets arrangement). Taken together, the ability 
of 1 to modulate the Aβ42 aggregation pathway eliminating the 
characteristic cytotoxic oligomers is a step forward in the 
development of compounds with the capacity to control the 
trigger and/or progression of AD. Despite the higher activity of 
1, it is clear that 2 is also able to interact with Aβ42 and reduce 
its cytotoxicity towards the neuroblastoma cell line SH-SY5Y.
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